MEDICAL TREATMENT OF TOXIC GOITER IN AN AREA OF IODINE DEFICIENCY*

FEREYDOON AZIZI, M.D.

From the Department of Medicine, Taleghani Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

ABSTRACT

The response to methimazole [1-methyl-2-mercapto-imidazole (MMI)] therapy, 10 mg twice daily in 15 patients and propylthiouracil (PTU) therapy, 100 mg twice daily in 10 patients with diffuse toxic goiter was evaluated in an area of iodine deficiency (Tehran).

The mean free T4 index (FT4I) decreased from 22.7 ± 6.8 (± SD) to 10.8 ± 2.8 in MMI-treated, and from 25.1 ± 6.8 to 13.2 ± 2.1 in PTU-treated patients, two weeks after treatment. The FT4I further decreased to 6.8 ± 4.3 and 8.5 ± 2.1 after four weeks of MMI and PTU administration, respectively. The mean free T3 index (FT3I) was 415 ± 90, 162 ± 44 and 117 ± 46 in MMI treated and 430 ± 80, 210 ± 45 and 140 ± 53 in PTU treated patients before and two and four weeks after treatment, respectively. The mean FT4I and FT3I had decreased more in the MMI treated groups as compared to the PTU treated patients, two weeks after treatment. In patients treated with MMI or PTU, 11 of 25 (44%) had subnormal FT4I after four weeks of treatment, of whom one had increased serum TSH.

These results indicate that treatment with less than the recommended doses of thionamide compounds causes a rapid decline of thyroid hormone indices in patients residing in Tehran. The dosage of thionamide compounds as well as the duration of therapy with the initial doses necessary to induce euthyroidism, should be evaluated in various parts of the world.


INTRODUCTION

In hyperthyroid patients treated with thionamide compounds, a reduction of the serum concentrations of thyroid hormones occurs after a latent period. Thus, it has been shown that thionamide compounds do not effect the release of thyroid hormones. The latent period is influenced by the quantity of hormones initially present in the gland, their rate of release, and the dosage of thionamide used.1-3

We have previously reported that treatment with the recommended doses of methimazole (MMI) rapidly causes hypothyroidism in patients residing in Tehran, an area of iodine deficiency.4

In the present study, we have evaluated the effect of lower doses of MMI and propylthiouracil (PTU) in patients with diffuse toxic goiter and in pregnant patients with hyperthyroidism in Tehran.

MATERIALS AND METHODS

Untreated patients with diffuse toxic goiter received antithyroid drugs for four weeks. A group of 15 patients, 10 women and five men, received MMI, 10 mg twice daily (group A). Another group of 10 patients,

* A portion of this work was presented at the Third Asian & Oceana Thyroid Association Meeting, Bangkok, 1986.
Medical treatment Toxic Goiter

![Graph](image)

**Fig. 1.** The effect of PTU therapy (100 mg twice daily) on mean FT$_4$I and FT$_3$I in 10 patients with diffuse toxic goiter residing in Tehran. Normal ranges: FT$_4$I, 4.5-13.0; FT$_3$I, 50-200.

seven women and three men, received PTU, 100 mg twice daily (group B). Methimazole, 10 mg twice daily, was also given to eight pregnant patients with diffuse toxic goiter for four weeks (group C).

Clinical status, serum concentrations of T$_4$, T$_3$ and TSH as well as T$_3$ resin uptake were evaluated before and after treatment. The free T$_4$ index (FT$_4$I) and free T$_3$ index (FT$_3$I) then were calculated.

Normal ranges in 180 normal subjects were: FT$_4$I, 4.5-13.5; and FT$_3$I, 80-200.

**RESULTS**

Group A: In patients treated with MMI, 10 mg twice daily, serum FT$_4$I decreased from $22.7 \pm 6.8$ to $12.1 \pm 2.5$ (p $< 0.001$) eight days after treatment, and 10 of 15 patients achieved normal FT$_4$I values. 14 days after treatment, FT$_4$I had decreased further to $10.8 \pm 2.5$. 13 of 15 patients had a normal FT$_4$I at this time. Four weeks after treatment, the mean FT$_4$I was $6.8 \pm 4.3$. It was subnormal in seven (46%) patients, one of whom had increased serum TSH. Minor symptoms of weight gain, dry skin and weakness were reported by four patients. FT$_4$I values were $415 \pm 60$, $197 \pm 36$, $162 \pm 44$ and $117 \pm 46$, before treatment; and $84$, $14$, and $28$ days after treatment, respectively. The age of the patients, size of goiter, and baseline values of the FT$_4$I and FT$_3$I were not significantly different in those who became hypothyroid and those who did not.

Group B (Fig. 1): In patients treated with PTU, 100 mg twice daily, FT$_4$I decreased from $25.1 \pm 6.8$ to $13.2 \pm 2.1$ (p $= 0.001$) two weeks after treatment. In seven of 10 patients, FT$_4$I had decreased to normal values at this time. Four weeks after treatment, mean FT$_4$I was $8.5 \pm 2.1$ and it was subnormal in four (40%) patients. FT$_3$I values were $430 \pm 80.2$, $180 \pm 45$, $140 \pm 35$, before, and $14$ and $28$ days after treatment, respectively. At the end of four weeks, one patient had a subnormal FT$_3$I. None had an increase in TSH.

The effects of MMI and PTU on thyroid hormone indices are compared in Table I. It appears that, at least two weeks after treatment, the effect of MMI on inhibition of thyroid hormone synthesis is slightly greater than PTU.

Group C: The effect of MMI therapy (10 mg twice daily for four weeks) on mean FT$_4$I and FT$_3$I levels in eight patients with diffuse toxic goiter is shown in Table II.

After four weeks of treatment, FT$_4$I was subnormal in three (40%) patients. Thereafter, all patients were effectively maintained euthyroid with a daily dose of 5 mg MMI throughout pregnancy. In one patient, the dosage had to be diminished to 2.5 mg daily.
DISCUSSION

In a previous study we have shown that treatment of patients with toxic goiter with daily doses of 30 mg MMI, which causes mild to moderate decrease in thyroid hormone concentration in areas of iodine sufficiency, results in clinical and biochemical evidences of hypothyroidism in almost half of patients treated for four weeks in Tehran. The present study demonstrates that treatment of diffuse toxic goiter with divided doses of 10 mg MMI or 100 mg PTU twice daily in patients residing in Tehran, reduces free thyroid hormone indices to half of pre-treatment values within two weeks. 11 of 25 (44%) patients had FT$_3$ values below the normal range after one month of therapy while at that time, one patient had clinical evidence of hypothyroidism and elevated serum TSH concentration.

A rapid fall in FT$_3$ and FT$_4$ was also observed in pregnant thyrotoxic patients after administration of 10 mg MMI twice daily. In contrast to high doses of MMI needed to treat thyrotoxicosis in pregnant women in areas of iodine sufficiency, it appears that low doses are effective in areas of iodine deficiency, perhaps minimizing the chance of adverse reactions in mother and fetus.

Thionamide compounds inhibit iodination of thyroglobulin tyrosine residues and the coupling of iodotyrosines, most likely by inhibiting thyroid peroxidase. Therefore thionamide drugs inhibit the synthesis of thyroid hormones; however, they do not affect the rate of release of thyroid hormones. Propylthiouracil (PTU) also impairs the conversion of T$_4$ to T$_3$ in the peripheral tissues, but MMI does not.

Thionamides were introduced into clinical medicine in 1943, a time when in the U.S. iodide deficiency had already been prevented by provision of iodized salt. Therefore, the initial studies of the effect of thionamide compounds in the treatment of hyperthyroidism were carried out in areas of iodine sufficiency. In 1950, doses of PTU recommended by Astwood and Williams were 200-400 mg daily (average, 300 mg) and were increased to 300-600 mg daily in later reports. The recommended dosage of MMI is about one tenth that of PTU. It has been suggested that treatment with the usual recommended dosage and regimen restores normal metabolic rate and serum concentration of thyroid hormone within 6 weeks to 3 months.

Environmental iodine intake may affect the response to thionamide therapy in patients with hyperthyroidism in several ways. Firstly, thyroid hormone stores within the thyroid follicles may be very little in patients residing in an area of iodine deficiency. Therefore inhibition of synthesis of thyroid hormones by MMI may cause a rapid decline in serum thyroid hormone concentration in patients residing in areas of iodine deficiency. Iodine deficiency has been clearly demonstrated in Tehran and suburbs. Secondly, intrathyroidal metabolism of MMI may be decreased in patients residing in areas of iodine deficiency. Reduced intrathyroidal metabolism of thionamide compounds previously was found in the thyroids of rats fed a low iodine diet. Despite a great increase in the size and peroxidase activity of the thyroid, MMI inhibition of thyroid peroxidase is competitive with iodide and high concentrations of intrathyroidal iodine may inhibit its activity. Therefore, MMI may impair the conversion of T$_4$ to T$_3$ in these patients.

Table II: FT$_4$ and FT$_3$ indices in eight pregnant patients with diffuse toxic goiter before and after treatment with methimazole (20 mg/d for four weeks).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>FT$_4$ (Before)</th>
<th>FT$_4$ (After)</th>
<th>FT$_3$ (Before)</th>
<th>FT$_3$ (After)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO. 1</td>
<td>13.2</td>
<td>9.2</td>
<td>410</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>24.0</td>
<td>1.4</td>
<td>530</td>
<td>90</td>
</tr>
<tr>
<td>3</td>
<td>19.6</td>
<td>2.2</td>
<td>490</td>
<td>95</td>
</tr>
<tr>
<td>4</td>
<td>26.0</td>
<td>8.0</td>
<td>680</td>
<td>230</td>
</tr>
<tr>
<td>5</td>
<td>20.5</td>
<td>12.2</td>
<td>720</td>
<td>165</td>
</tr>
<tr>
<td>6</td>
<td>19.0</td>
<td>7.2</td>
<td>450</td>
<td>190</td>
</tr>
<tr>
<td>7</td>
<td>18.5</td>
<td>9.2</td>
<td>520</td>
<td>140</td>
</tr>
<tr>
<td>8</td>
<td>27.2</td>
<td>0.5</td>
<td>350</td>
<td>82</td>
</tr>
<tr>
<td>Mean</td>
<td>26.6</td>
<td>6.2</td>
<td>518</td>
<td>136</td>
</tr>
<tr>
<td>SD</td>
<td>4.9</td>
<td>4.3</td>
<td>127</td>
<td>54</td>
</tr>
<tr>
<td>Normal range</td>
<td>4.5-13.0</td>
<td>80-200</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F. Azzizi, M.D.
We conclude that recommended dosages and regimens of thionamide administration cannot be employed for the treatment of diffuse toxic goiter in Tehran and perhaps in other areas of iodine deficiency. In such patients we recommend starting doses of 10 mg MMI or 100 mg PTU, twice daily, for two weeks, and 5 mg twice daily, for an additional two weeks. Evaluation of serum concentrations of thyroid hormones after two and four weeks of therapy may be helpful in deciding further optimum dosage of MMI or PTU. Similar studies should be carried out in other parts of the world, in particular in countries with inadequate daily iodide intake.

REFERENCE